ERBB2 and breast cancer: Among these, HER2-positive (HER2+) BC is characterized by HER2 overexpression driven by ERBB2 gene amplification, accounting for approximately 15% to 20% of all invasive BCs.[4] HER2+ BC usually exhibits high aggressiveness and relatively poor prognosis, but it shows good responses to HER2-targeted therapies.